Medicinal – Page 146

Disseminated subcutaneous sporotrichosis in an immunocompetent patient: A case report and a systematic literature review

mycolabadmin

A 74-year-old man developed painful red masses on his arm and hand after being stuck by a tree branch. Tests identified the infection was caused by a fungus called Sporothrix schenckii. Despite having a normal immune system, the infection had spread across his arm in an unusual pattern. Treatment with an antifungal medication called itraconazole completely healed the lesions within four months without any scarring.

Persister cells in human fungal pathogens

mycolabadmin

Some fungal infections fail to respond to antifungal drugs even when the fungus should be susceptible to treatment. This happens because certain fungal cells can enter a dormant ‘sleep-like’ state that helps them survive drug exposure. These dormant cells, called persisters, are able to hide from medications by reducing their metabolism and enhancing their protective defenses. Understanding how these persister cells form and survive could lead to better treatments for serious fungal infections.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing essential zinc that the fungus needs to survive. The study found that nitroxoline was highly effective against all tested fungal strains, including those resistant to modern antifungal drugs, suggesting it could be a promising alternative treatment for serious fungal infections.

Tracing the Origin and Evolution of the Fungal Mycophenolic Acid Biosynthesis Pathway

mycolabadmin

Mycophenolic acid is an important drug that helps transplant patients by preventing their immune systems from rejecting new organs. Scientists studied the genes that fungi use to make this drug and found it in several fungal species. They discovered that this ability to produce the drug evolved a long time ago in fungi but was lost in most species over time, remaining only in a few special fungi.

Addressing Patient Requests to Add Dietary Supplements to Their Cancer Care—A Suggested Approach

mycolabadmin

Cancer patients often want to use dietary supplements alongside their conventional cancer treatments to manage side effects, boost immunity, and feel more in control of their health. Many patients don’t tell their doctors about supplement use because they worry about judgment or think doctors won’t understand their interests. This paper suggests doctors should have open, non-judgmental conversations with patients about supplements, evaluate their safety and effectiveness using reliable information sources, and work together with patients to make informed decisions that keep them safe while respecting their choices.

Coexistence of Malassezia Species and Microsporum canis in the Lesions of Adult with Tinea Capitis

mycolabadmin

A 60-year-old woman developed unusual hair loss and scalp inflammation that looked like dandruff but was actually a fungal infection caused by multiple fungi working together. Doctors found three different fungi in her scalp samples: one dermatophyte and two Malassezia species. Lab experiments showed that the Malassezia fungi actually helped the main disease-causing fungus grow better, which explains why the condition looked different from typical cases. After three months of antifungal medication, her symptoms cleared and her hair grew back.

The Major Stilbene Compound Accumulated in the Roots of a Resistant Variety of Phoenix dactylifera L. Activates Proteasome for a Path in Anti-Aging Strategy

mycolabadmin

Researchers found that date palm roots from disease-resistant varieties contain a special compound called 3,3′,4,5,5′-pentahydroxy-trans-stilbene that acts as a natural antioxidant and anti-aging agent. This compound can protect aging skin cells by activating the proteasome, which is like the cell’s recycling system that removes damaged proteins. The findings suggest this natural compound could potentially help slow down skin aging and protect against age-related diseases.

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model

mycolabadmin

Researchers developed tiny nanoparticle carriers coated with a fungal enzyme that helps them cross the protective barrier around the brain. These particles were loaded with an antifungal drug to treat brain infections caused by Cryptococcus neoformans. In laboratory tests, the Mpr1-coated particles successfully penetrated the blood-brain barrier better than regular nanoparticles and were more effective at killing the fungal cells.

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

mycolabadmin

This study examines how Trikafta, a new cystic fibrosis medication, affects a common fungal lung infection (Aspergillus fumigatus). The researchers found that Trikafta doesn’t directly kill the fungus but does make it more susceptible to antifungal drugs and improves lung clearance. Surprisingly, at high concentrations, the medication actually reduced the immune response against the fungus in immune cells, suggesting the need for careful monitoring of patients on this therapy.

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development

mycolabadmin

Researchers used a special microarray technology to identify immune responses in blood samples from people infected with Candida yeast. They found that early infections trigger antibodies against certain sugar structures, while later infections produce different antibodies. Three specific sugar molecules showed promise as markers for diagnostic tests and vaccine development against dangerous yeast infections.

Research Topic: Medicinal